Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565739 | 0.85 | CYP3A4 (0.53) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL277940 | 0.85 | CYP3A4 (0.53) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| Methane SCHEMBL11583017 | 0.83 | CYP3A4 (0.52) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL14540599 | 0.71 | HSD17B10 (0.46) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL227614 | 0.70 | TDP1 (0.45) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL29862788 | 0.70 | TDP1 (0.45) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL18961264 | 0.70 | TDP1 (0.46) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL462305 | 0.69 | TDP1 (0.70) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL29709073 | 0.69 | TDP1 (0.70) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL940978 | 0.68 | SRD5A2 (0.46) | CYP3A4TDP1ALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CYP3A4 2166/4885TDP1 2092/4885ALDH1A1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.